A Phase 2, Randomized, Double-masked, Placebo-controlled Study of XOPH5 Ointment for Reduction of Lower Lid Steatoblepharon

Trial Profile

A Phase 2, Randomized, Double-masked, Placebo-controlled Study of XOPH5 Ointment for Reduction of Lower Lid Steatoblepharon

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Apr 2016

At a glance

  • Drugs XAF 5 (Primary)
  • Indications Lid disorders; Subcutaneous fat disorders
  • Focus Therapeutic Use
  • Sponsors Topokine Therapeutics
  • Most Recent Events

    • 22 Apr 2016 According to an Allergan media release, the primary endpoint (Lower Eyelid Steatoblepharon Severity (LESS) Score--Clinician-Reported safety_issue: No description: Photonumeric scale, range 0-4, 0 is absence of steatoblepharon, 4 is very severe steatoblepharon. time_frame: 11 weeks) has been met.
    • 05 Jan 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 18 Sep 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top